Drug Search Results
Using advanced filters...
Advanced Search [+]

Metronidazole

Alternative Names: metronidazole, flagyl, metronidazol, metrogel, arilin, tricom, noritate, metrogyl, vandazole, nuvessa, metrocream, metrolotion, metro i.v. in plastic container, metromidol, metro i.v., protostat, satric, rosadan, pylera, helidac, helidac therapy, LIKMEZ
Latest Update: 2025-03-18
Latest Update Note: News Article

Product Description

Metronidazole is one of the mainstay drugs for the treatment of anaerobic bacterial infections, protozoal infections, and microaerophilic bacterial infections. It is cytotoxic to facultative anaerobic microorganism. Metronidazole diffuses into the organism, inhibits protein synthesis by interacting with DNA and causing a loss of helical DNA structure and strand breakage. Therefore, it causes cell death in susceptible organisms. (Sourced from: https://www.ncbi.nlm.nih.gov/books/NBK539728/)

Mechanisms of Action: Nucleic Acid Synthesis Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral,Topical,Intravenous

FDA Designation: None *

Approval Status: Approved

Approved Countries: Algeria | Argentina | Australia | Austria | Bangladesh | Belgium | Bosnia | Brazil | Bulgaria | Canada | Chile | China | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Japan | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Morocco | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam

Approved Indications: None

Known Adverse Events: None

Company: Pfizer
Company Location: NEW YORK NY 10017
Company CEO: Albert Bourla
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Metronidazole

Countries in Clinic: Australia, China, Denmark, France, Romania, Spain, United States

Active Clinical Trial Count: 13

Highest Development Phases

Phase 3: Appendicitis|Candidiasis, Vulvovaginal|Hidradenitis Suppurativa|Peritonitis|Vaginal Discharge|Vaginitis|Vaginosis, Bacterial

Phase 2: Adenoma|Colorectal Cancer|Diverticulitis|Pouchitis

Phase 1: Atrial Fibrillation|Healthy Volunteers

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

2024-517764-38-00

P2

Unknown Status

Pouchitis

2027-08-02

NNMAIS 01/2021

P3

Unknown Status

Vaginosis, Bacterial|Candidiasis, Vulvovaginal

2026-07-01

DIREBIOT

P2

Unknown Status

Diverticulitis

2025-12-31

ABCESS2

P3

Not yet recruiting

Hidradenitis Suppurativa

2025-12-15

Recent News Events